US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.
first published: Jul 25, 2016 12:00 pm
A collection of the most-viewed Moneycontrol videos.
Can Nifty Claw Back Above 25,600 Or Will Sensex Expiry Cap The Upside?| Opening Bell Live
Gold ETFs vs Silver ETFs | Which One Is Your Wealth Buddy?
Nifty Sees Triple-Digit Cut Despite Strong Q2 From SBI & M&M; All Sectors In Red | Closing Bell Live
Groww's Rs 6,632 Cr IPO Opens For Subscription | Management On Future Path | IPO Watch Live
